BioGraphene
Advance Graphene-Based Technology to Save and Improve People's Lives
3 employees · est. 2017 · Los Angeles, United States
Neuron23
Combining cutting-edge science, human genetics, and a patient-centered approach to transform how we treat Parkinson’s.
28 employees · est. 2018 · South San Francisco, United...
BioGraphene is the older company (2017 vs 2018); Neuron23 is the larger of the two.
Side-by-Side Comparison
| Metric | BioGraphene | Neuron23 |
|---|---|---|
| Founded | ||
| Founded | 2017 older | 2018 |
| Headquarters | ||
| Headquarters | Los Angeles, United States | South San Francisco, United States |
| Employees | ||
| Employees | 3 | 28 larger |
| Industry | ||
| Industry | Biotechnology, Health Care, Pharmaceutical | Not tracked yet |
| Funding Stage | ||
| Funding Stage | Series Unknown | Series D |
| Total Funding | ||
| Total Funding | Not tracked yet | $230.00M |
| Funding Rounds | ||
| Funding Rounds | 1 | 4 |
| Services | ||
| Services | Not tracked yet | Development of precision medicine for Parkinson's Disease, Clinical trials for novel therapeutic approaches, Research and development in neuroimmunology and neuroscience |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with Parkinson's Disease, Healthcare providers specializing in neurology, Pharmaceutical and biotechnology investors |
| Taxonomy | ||
| Taxonomy | Biotech Startup, Graphene-based Drugs, Neurodegenerative Diseases, Parkinson's Disease, Alzheimer's Disease, Niemann-Pick Disease Type C, Spin-off Company, Seoul National University, California, Biomedical Applications, Nanomedicines, Lysosomal Storage Diseases, Rare Diseases, Graphene Technology, Nanotechnology | Precision Medicine, Parkinson's Disease, Neurodegenerative Diseases, Human Genetics, Biomarker Platform, Drug Discovery, Neurological Diseases, Alzheimer's Disease, Clinical-stage Biotechnology, Hyperactive LRRK2, Patient-centered Approach, Neuroinflammatory Diseases, Autoimmune Diseases |
| Website | ||
| Website | bio-graphene.com | neuron23.com |
About BioGraphene
BioGraphene is a biotech startup focused on revolutionizing the treatment of neurodegenerative diseases through advanced graphene-based drugs. The company's slogan "Advance Graphene-Based Technology to Save and Improve People's Lives" encapsulates its mission to make a meaningful impact on healthcar...
About Neuron23
Neuron23, founded in 2018, is a clinical-stage biotechnology company based in the United States. The company is pioneering advancements in precision medicine, specifically targeting Parkinson’s disease driven by hyperactive LRRK2. By integrating cutting-edge science with human genetics and its propr...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at BioGraphene and Neuron23 — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at BioGraphene and Neuron23 — by email.
Frequently Asked Questions
Compare BioGraphene with someone else
Start typing a company name or domain.